Amneal Pharmaceuticals (AMRX)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.28 (+3.28%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Key Insights

Critical company metrics and information
  • Share Price

    $8.81
  • Market Cap

    $2.73 Billion
  • Total Outstanding Shares

    309.84 Million Shares
  • Total Employees

    7,700
  • Dividend

    No dividend
  • IPO Date

    May 7, 2018
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.amneal.com

Historical Stock Splits

If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution DateSplit Amount
August 26, 20131-for-25 (Reverse Split)

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow$-17.26 Million
Net Cash Flow From Investing Activities, Continuing$-78.63 Million
Exchange Gains/Losses$58000.00
Net Cash Flow From Financing Activities$-251.42 Million
Net Cash Flow, Continuing$-17.20 Million
Net Cash Flow From Investing Activities$-78.63 Million
Net Cash Flow From Financing Activities, Continuing$-251.42 Million
Net Cash Flow From Operating Activities, Continuing$312.84 Million
Net Cash Flow From Operating Activities$312.84 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$-179.73 Million
Income/Loss From Continuing Operations After Tax$-146.48 Million
Preferred Stock Dividends And Other Adjustments$4.73 Million
Cost Of Revenue$1.73 Billion
Basic Earnings Per Share$0.86
Research and Development$182.53 Million
Diluted Earnings Per Share$0.85
Net Income/Loss$-146.48 Million
Net Income/Loss Available To Common Stockholders, Basic$-184.45 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$4.73 Million
Nonoperating Income/Loss$-310.88 Million
Operating Income/Loss$187.73 Million
Income/Loss From Continuing Operations Before Tax$-123.16 Million
Gross Profit$947.39 Million
Selling, General, and Administrative Expenses$456.75 Million
Other Operating Expenses$120.38 Million
Revenues$2.68 Billion
Operating Expenses$759.67 Million
Diluted Average Shares$328.54 Million
Basic Average Shares$331.46 Million
Benefits Costs and Expenses$2.80 Billion
Income Tax Expense/Benefit$23.32 Million
Net Income/Loss Attributable To Noncontrolling Interest$37.98 Million
Costs And Expenses$2.80 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Long-term Debt$2.39 Billion
Equity$-93.57 Million
Assets$3.46 Billion
Current Assets$1.51 Billion
Equity Attributable To Parent$-93.43 Million
Noncurrent Liabilities$2.40 Billion
Liabilities And Equity$3.46 Billion
Wages$64.90 Million
Other Current Liabilities$795.31 Million
Other Non-current Assets$736.48 Million
Equity Attributable To Noncontrolling Interest$135000.00
Liabilities$3.49 Billion
Other Non-current Liabilities$5.15 Million
Temporary Equity$59.89 Million
Fixed Assets$431.02 Million
Inventory$596.36 Million
Other Current Assets$916.93 Million
Accounts Payable$235.00 Million
Intangible Assets$780.19 Million
Noncurrent Assets$1.95 Billion
Current Liabilities$1.10 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.